<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867707</url>
  </required_header>
  <id_info>
    <org_study_id>2038203</org_study_id>
    <nct_id>NCT04867707</nct_id>
  </id_info>
  <brief_title>Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes</brief_title>
  <acronym>NAED</acronym>
  <official_title>Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a&#xD;
      therapeutic strategy to restore endothelial function in T2D patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty subjects will complete five days of treatment with zanamivir. Baseline measurements&#xD;
      will be taken before the initiation of treatment, as well as after the conclusion of the&#xD;
      treatment period (i.e., a total of two assessment visits per subject). Assessment visits will&#xD;
      include: vitals (such as blood pressure, heart rate), fasting blood work for plasma&#xD;
      neuraminidase activity, plasma sialic acid, plasma glucose and plasma insulin, brachial&#xD;
      artery FMD, and glycocalyx integrity assessment via Glycocheck.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group design with 20 subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in glycocalyx integrity</measure>
    <time_frame>0 and 5 days</time_frame>
    <description>Measure of glycocalyx integrity via Glycocheck. Glycocalyx integrity measures will be performed non-invasively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular function</measure>
    <time_frame>0 and 5 days</time_frame>
    <description>Flow mediated dilation (FMD) in arm. Brachial artery FMD measures will be performed non-invasively via Ultrasound.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Zanamivir treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will receive 5 days of treatment with a zanamivir inhaler.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanamivir</intervention_name>
    <description>5 days of treatment with 10mg zanamivir inhaler BID</description>
    <arm_group_label>Zanamivir treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women with a BMI of 25-39 kg/m2&#xD;
&#xD;
          2. Ages 45-64 years at randomization.&#xD;
&#xD;
          3. Diagnosis of T2D classified based on physician diagnosis.&#xD;
&#xD;
          4. No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cardiovascular disease including myocardial infraction, heart failure, coronary artery&#xD;
             disease, stroke&#xD;
&#xD;
          2. History of chronic renal or hepatic disease&#xD;
&#xD;
          3. Active cancer&#xD;
&#xD;
          4. Autoimmune diseases&#xD;
&#xD;
          5. Immunosuppressant therapy&#xD;
&#xD;
          6. Hormone replacement therapy&#xD;
&#xD;
          7. Excessive alcohol consumption (&gt;14 drinks/week for men, &gt;7 drinks/week for women)&#xD;
&#xD;
          8. Current tobacco use&#xD;
&#xD;
          9. Pregnancy (Premenopausal women will be required to complete a urine pregnancy test&#xD;
             before participation)&#xD;
&#xD;
         10. History of asthma or chronic obstructive pulmonary disease.&#xD;
&#xD;
         11. History of allergic reaction to lactose or milk proteins&#xD;
&#xD;
         12. Intranasal live attenuated influenza vaccine (LAIV) given within 2 weeks before&#xD;
             zanamivir administration or a planned dose within 48 hours after zanamivir&#xD;
             administration. Product insert states to avoid zanamivir administration with&#xD;
             intranasal live attenuated influenza vaccine (LAIV).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luis Martinez-Lemus, PhD</last_name>
    <phone>(573) 882-3244</phone>
    <email>martinezlemusl@missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaume Padilla, PhD</last_name>
    <phone>(573) 882-7056</phone>
    <email>padillaja@missouri.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Missouri, School of Medicine Clinical Research Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Burr, MS</last_name>
      <phone>573-884-1222</phone>
      <email>katherineburr@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Atkins, BSN</last_name>
      <phone>(573) 882-8591</phone>
      <email>wiesa@health.missouri.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Luis Martinez-Lemus, DVM, PhD</investigator_full_name>
    <investigator_title>Professor in Medical Pharmacology Physiology</investigator_title>
  </responsible_party>
  <keyword>endothelial dysfunction</keyword>
  <keyword>vascular function</keyword>
  <keyword>glycocalyx integrity assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanamivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

